Full
Outline
The bacterial endotoxin test (BET) is a key quality control method for controlling the pyrogen risk of injectable products and other sterile drugs. With the acceleration of the global integration in drug research and development, production and regulation, the harmonization of testing methods across various pharmacopoeias has become an inevitable trend. ICH Q4B guideline Annex 14 provides a harmonized assessment of the BET chapters in the United States Pharmacopeia (USP), European Pharmacopoeia (EP) and Japanese Pharmacopoeia (JP), and recommends their interchangeable use within the ICH region. The Pharmacopoeia of the People's Republic of China (ChP), as China's national drug standard, historically established its BET method based on the USP and has undergone continuous revisions to align with ICH harmonization efforts, gradually achieving international alignment. This article aims to conduct a detailed comparative analysis of the main differences between the BET in ChP 2020 edition and the ICH harmonized text, based on ICH Q4B Annex 14 and the relevant chapters of the USP, EP and JP, and to explain the background, principles, main content, and ICH Q4B harmonization considerations underlying the revision of the BET in the ChP 2025 edition. The study shows that the BET in the ChP 2025 edition further converges with the ICH harmonized text in terms of method description format, requirements for revalidation of limulus amebocyte lysate (LAL) reagents sensitivity, and certain calculation parameters. At the same time, considering China's national conditions and drug safety, it retains Chinese characteristics in aspects such as water for testing requirements, the average body weight standard for calculating endotoxin limits, gel-clot interference test, and retest requirements for the limit test. This revision reflects the ChP's principle of actively participating in international harmonization while enhancing scientific rigor and international competitiveness of standards, while also taking into account domestic regulatory practices and public health, thereby laying a more solid foundation for achieving mutual recognition in drug regulation.
81
9
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
